Utilize este identificador para referenciar este registo: https://hdl.handle.net/1822/78222

Registo completo
Campo DCValorIdioma
dc.contributor.authorLamas, Nuno Jorgepor
dc.contributor.authorMartel, Arnaudpor
dc.contributor.authorNahon-Estève, Sachapor
dc.contributor.authorGoffinet, Samanthapor
dc.contributor.authorMacocco, Adampor
dc.contributor.authorBertolotto, Corinepor
dc.contributor.authorLassalle, Sandrapor
dc.contributor.authorHofman, Paulpor
dc.date.accessioned2022-06-03T11:17:07Z-
dc.date.available2022-06-03T11:17:07Z-
dc.date.issued2022-
dc.identifier.citationLamas, N.J.; Martel, A.; Nahon-Estève, S.; Goffinet, S.; Macocco, A.; Bertolotto, C.; Lassalle, S.; Hofman, P. Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions. Cancers 2022, 14, 96. https://doi.org/10.3390/cancers14010096por
dc.identifier.urihttps://hdl.handle.net/1822/78222-
dc.description.abstractUveal melanoma (UM) is the most common malignant intraocular tumour in the adult population. It is a rare cancer with an incidence of nearly five cases per million inhabitants per year, which develops from the uncontrolled proliferation of melanocytes in the choroid (≈90%), ciliary body (≈6%) or iris (≈4%). Patients initially present either with symptoms like blurred vision or photopsia, or without symptoms, with the tumour being detected in routine eye exams. Over the course of the disease, metastases, which are initially dormant, develop in nearly 50% of patients, preferentially in the liver. Despite decades of intensive research, the only approach proven to mildly control disease spread are early treatments directed to ablate liver metastases, such as surgical excision or chemoembolization. However, most patients have a limited life expectancy once metastases are detected, since there are limited therapeutic approaches for the metastatic disease, including immunotherapy, which unlike in cutaneous melanoma, has been mostly ineffective for UM patients. Therefore, in order to offer the best care possible to these patients, there is an urgent need to find robust models that can accurately predict the prognosis of UM, as well as therapeutic strategies that effectively block and/or limit the spread of the metastatic disease. Here, we initially summarized the current knowledge about UM by compiling the most relevant epidemiological, clinical, pathological and molecular data. Then, we revisited the most important prognostic factors currently used for the evaluation and follow-up of primary UM cases. Afterwards, we addressed emerging prognostic biomarkers in UM, by comprehensively reviewing gene signatures, immunohistochemistry-based markers and proteomic markers resulting from research studies conducted over the past three years. Finally, we discussed the current hurdles in the field and anticipated the future challenges and novel avenues of research in UM.por
dc.description.sponsorshipN.J.L. would like to thank all members of the Laboratory of Clinical and Experi-mental Pathology (LPCE), Centre Hospitalier Universitaire de Nice, Nice, France; and all members of the Anatomic Pathology Service, Pathology Department, Centro Hospitalar e Universitario do Porto,Porto, Portugal, especially to JoseRamon Vizcaino (Head of Service), Joana Raposo Alves (Advisor ofPathology Training), Andre Coelho, David Tente and Francisca Emanuel Costa for their continuous support and help in the developmentpor
dc.language.isoengpor
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)por
dc.rightsopenAccesspor
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/por
dc.subjectUveal melanomapor
dc.subjectPrognostic factorspor
dc.subjectBiomarkerspor
dc.subjectMetastasespor
dc.subjectSurvivalpor
dc.subjectMolecular pathologypor
dc.titlePrognostic biomarkers in uveal melanoma: the status quo, recent advances and future directionspor
dc.typearticlepor
dc.peerreviewedyespor
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/14/1/96por
oaire.citationStartPage1por
oaire.citationEndPage44por
oaire.citationIssue1por
oaire.citationVolume14por
dc.date.updated2022-01-10T14:38:27Z-
dc.identifier.eissn2072-6694-
dc.identifier.doi10.3390/cancers14010096por
dc.subject.wosScience & Technologypor
sdum.journalCancerspor
oaire.versionVoRpor
dc.identifier.articlenumber96por
Aparece nas coleções:BUM - MDPI

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
cancers-14-00096-v2.pdf4 MBAdobe PDFVer/Abrir

Este trabalho está licenciado sob uma Licença Creative Commons Creative Commons

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID